article

Machine learning in biopharmaceutical manufacturing

The biotechnology industry is expected to increase the production of new biopharmaceuticals.1 Biopharmaceuticals require high-quality standards, high initial investments for approval and introduction into the market as well as continued investment in manufacturing.2,3

In order to achieve profitable and sustainable manufacturing of biopharmaceuticals, bioprocess and bioproduct development must be planned and executed concurrently throughout the production lifecycle.4 Currently, bioprocess development is a critical bottleneck for the successful implementation of innovation obtained during bioproduct development.5 The majority of host-cell screening, initial conditions, material attributes and bioprocess parameter in-depth optimisation, as well as the identification of relationships between critical process parameters (CPP) and critical quality attributes (CQA), happens at an early stage of development during the implementation and execution of design of experiments (DoE) towards the established quality by design (QbD) paradigm.4,6

The rest of this content is restricted - login or subscribe free to access

Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 

Send this to a friend